alexa Late relapse of testicular cancer.
Oncology

Oncology

Chemotherapy: Open Access

Author(s): Lipphardt ME, Albers P

Abstract Share this page

Abstract Due to its unique biological behavior, late relapse (LR) of testicular cancer has recently been described as an own tumor entity. It is currently defined as tumor recurrence more than 2 years after complete remission following primary treatment including chemotherapy. The incidence ranges from 2 to 6\%, with a median relapse-free interval of 5.4-7.1 years from the initial treatment. Although histology shows a germ cell tumor (GCT) origin, the clinical biology is different. The dominant characteristics are slow tumor growth and chemoresistance. Molecular analysis currently focuses on the mechanisms of drug resistance. The initial response to chemotherapy is less than 30\% and in most cases complete surgical resection remains the only treatment option with favorable long-term results. The most common site of LR is the retroperitoneum, with undifferentiated cancer (yolk sac) being the most frequent histology. In most cases, patients have already undergone previous retroperitoneal surgery. The overall cure rate is only about 50\%, hence, adequate treatment of the primary tumor is essential to prevent the development of LR. This article was published in World J Urol and referenced in Chemotherapy: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords